ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
BioAge Labs Inc

BioAge Labs Inc (BIOA)

4.64
-0.06
(-1.28%)
Cerrado 14 Enero 3:00PM
4.64
0.00
( 0.00% )
Pre Mercado: 3:21AM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
4.64
Postura de Compra
4.42
Postura de Venta
5.00
Volume Operado de la Acción
20
0.00 Rango del Día 0.00
3.85 Rango de 52 semanas 26.41
Capitalización de Mercado [m]
Precio Anterior
4.64
Precio de Apertura
-
Última hora de negociación
03:01:51
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
773,077
Acciones en circulación
35,848,738
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.60
Beneficio por acción (BPA)
-1.78
turnover
-
Beneficio neto
-63.85M

Acerca de BioAge Labs Inc

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights in... BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Newark, Delaware, USA
Fundado
-
BioAge Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BIOA. The last closing price for BioAge Labs was US$4.64. Over the last year, BioAge Labs shares have traded in a share price range of US$ 3.85 to US$ 26.41.

BioAge Labs currently has 35,848,738 shares in issue. The market capitalisation of BioAge Labs is US$166.34 million. BioAge Labs has a price to earnings ratio (PE ratio) of -2.60.

BIOA Últimas noticias

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The...

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class...

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related...

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share...

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash...

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...

BioAge Labs to Present at Jefferies London Healthcare Conference

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.6969-13.05814236735.33695.34684.313859324.81107895CS
4-0.16-3.333333333334.87.153.9710915585.3274659CS
12-19.06-80.421940928323.725.33.857730777.85321621CS
26-17.86-79.377777777822.526.413.8571289610.47814419CS
52-17.86-79.377777777822.526.413.8571289610.47814419CS
156-17.86-79.377777777822.526.413.8571289610.47814419CS
260-17.86-79.377777777822.526.413.8571289610.47814419CS

BIOA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de BioAge Labs?
El precio actual de las acciones de BioAge Labs es US$ 4.64
¿Cuántas acciones de BioAge Labs están en circulación?
BioAge Labs tiene 35,848,738 acciones en circulación
¿Cuál es la capitalización de mercado de BioAge Labs?
La capitalización de mercado de BioAge Labs es USD 166.34M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de BioAge Labs?
BioAge Labs ha negociado en un rango de US$ 3.85 a US$ 26.41 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de BioAge Labs?
El ratio precio/beneficio de BioAge Labs es -2.6
¿Cuál es la moneda de reporte de BioAge Labs?
BioAge Labs presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de BioAge Labs?
El último beneficio anual de BioAge Labs es USD -63.85M
¿Cuál es la dirección registrada de BioAge Labs?
La dirección registrada de BioAge Labs es 131 CONTINENTAL DRIVE, SUITE 301, NEW CASTLE, NEWARK, DELAWARE, 19713
¿Cuál es la dirección del sitio web de BioAge Labs?
La dirección del sitio web de BioAge Labs es www.bioagelabs.com
¿En qué sector industrial opera BioAge Labs?
BioAge Labs opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SGBXSafe and Green Holdings Corporation
US$ 1.04
(92.59%)
15.1M
HSDTHelius Medical Technologies Inc
US$ 1.20
(73.41%)
7.56M
VMARVision Marine Technologies Inc
US$ 2.195
(56.79%)
6.32M
DXRDaxor Corporation
US$ 11.83
(40.33%)
11
PVBCProvident Bancorp Inc
US$ 13.99
(29.18%)
8
GLACGlobal Lights Acquisition Corporation
US$ 7.00
(-34.46%)
200
EBMTEagle Bancorp Montana Inc
US$ 10.01
(-31.90%)
5
BBGIBeasley Broadcast Group Inc
US$ 6.11
(-29.68%)
1
RAPPRapport Therapeutics Inc
US$ 9.01
(-29.00%)
3
CRKNCrown Electrokinetics Corporation
US$ 0.0638
(-27.99%)
1.33M
SGBXSafe and Green Holdings Corporation
US$ 1.04
(92.59%)
15.1M
GCTKGlucoTrack Inc
US$ 0.10
(-18.03%)
7.73M
HSDTHelius Medical Technologies Inc
US$ 1.20
(73.41%)
7.56M
VMARVision Marine Technologies Inc
US$ 2.195
(56.79%)
6.32M
SHViShares Short Treasury Bond ETF
US$ 110.27
(0.01%)
4.49M
WolfofMia WolfofMia 6 minutos hace
Wow you an AF apologist now?

LMAO!
AVXL
TrendTrade2016 TrendTrade2016 16 minutos hace
SUPER STAR CEO RAN AWAY WITH THE LOOT..OLE SCHOOL RINSE THE DEBT...THOSE TORONTO BOYS WORKED YA GOOD HERE..SCAM IS DONE!
TWOH
Atlanta1 Atlanta1 20 minutos hace
so it looks like we're screwed
CRTG
P-Rawl P-Rawl 23 minutos hace
Have smallcapvoice given up on him or can he no longer afford their $5,500 a month fee? They haven't posted anything for weeks, apart from a notice about a forthcoming video back on December 17th which was meant to answer shareholder questions. Still no sign of that video.
SONG
Drugdoctor Drugdoctor 27 minutos hace
$GBIO .88 - Nasdaq Bios are hot! INSIDER-BUY-Quinn Anthony G. (Director) Buys 210,791 @ Avg Price: $0.96 - Balance Sheet
Total Cash (mrq)184.77M-Total Cash Per Share (mrq)2.77
GBIO
TrendTrade2016 TrendTrade2016 29 minutos hace
LMAO STOP PRETENDING
FNMA
lakers17 lakers17 30 minutos hace
Took a starter in SOLO at .0043

Contract 0xD61A8BbD5C6d8Cd9690a89616b33dC939C9FbDA9

https://x.com/SoloDePIN
TrendTrade2016 TrendTrade2016 30 minutos hace
THAT WAS A BULL RUN ALRIGHT...IT WAS WASHED UP TO ALLOW OWNERS TO RINSE THE RAG...LOST MAN!
RDAR
Cornerstone_Marketing Cornerstone_Marketing 34 minutos hace
I would be interested in knowing who you work for. NO REAL PERSON spends all day bashing and misdirecting people. 
Every post of yours is garbage - many are just scare tactics or posting articles on companies not related to Spzi to infer "something bad" is coming.

If in fact yo
SPZI
Iggy_Bot Iggy_Bot 35 minutos hace
Sooooooonnnnnnnnnnnnnnn
Guzzi62 Guzzi62 35 minutos hace
They don't, not possible.

It's the regulators that are slow, maybe understaffed, the UK economy is not in a good shape.
NWBO
Sooth_Sayer Sooth_Sayer 35 minutos hace
More dilution?
GORO
lakers17 lakers17 44 minutos hace
Locked and loaded in PAI now:

Q1 2025 is going to be a game changer for $PAI!

We’re rolling out ParaHub and ParaGen, pushing the boundaries of parallel computing with Parilix, and leveling up AI optimization with PACT. It's all about making AI deployment faster, smarter
PAI
FortunaFavetFortibus FortunaFavetFortibus 46 minutos hace
pre-conservatorship they were issuing dividends at $1-2/share per year on annually profits of $3-5B
with current profits 5X-4X that level, a $10/share div annually is on the high end but still within the math of that dividend model
and F&F are not entities that require much re-investme
FNMA
knrorrel knrorrel 50 minutos hace
I bought a third time yesterday and I think the stock will make a big upward move in the long term.

ALSCF
knrorrel knrorrel 51 minutos hace
great $ALSCF tweet https://x.com/AlsetAI/status/1876737840207347980?t=rj9nA2loOQyUKcASp_UzAA&s=19
ALSCF
QueenVic QueenVic 55 minutos hace
Warren might slip up and say "bail out". And then try to cover her tracks.

Too many unjustifiable words she has to question - 💤💤💤
A friggin waste of time she is
capgain capgain 58 minutos hace
Good morning, RR. “It’s critically important that, to the extent you can find anything that gives you an ability to be patient in this extremely dangerous and unprecedented crisis, that you do,” LOL, Just kidding :)

Straight up, I like all the home teams in the NFL this weekend. KC, D
Calvin Hobbes Calvin Hobbes 59 minutos hace
It's possible. They do need to update the GGSM one though as well and get all the info that is in filings in there as well. There is a lot of info they could add.
GGSM
QueenVic QueenVic 60 minutos hace
😂😁🫢

Elizabeth "Chief Princess of Running mouth" Warren was sooooo irrelevant at questioning the nominee Pete Hegseth (Secretary Dept of defense) and she and the cronies around her basically are people who word fight and bully their way- to no avail.
QueenVic QueenVic 1 hora hace
I felt the same way. It's too bad that people are suffering from this

The DEI is a farce, and places hired individuals that are not qualified for the jobs it's beyond mental and physical capabilities you need to be in tip top shape no matter what and on call 24/7.

The
threewheeler threewheeler 1 hora hace
01/15/2025 Expert Market IconCRTG The Coretec Group Inc. OTCQB Expert Market Common Stock
CRTG
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 hora hace
People who bought the december offering at $3 a share sure are tasting some pain. Surprise the underwriters arent supporting the stock better.
IBRX
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 hora hace
ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price
I wonder if the underwriters exercised this option or not. $3 share price doesnt look to great a deal at the moment.
IBRX
martyDg martyDg 1 hora hace
Does the big red in your nwbo position tell you it's derisked? LOL 
NWBO

Su Consulta Reciente

Delayed Upgrade Clock